Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development UpdateNovember 26, 2025 7:35 AM EST | Source: Sharp Therapeutics Corp.Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed interim consolidated financial statements for the three and nine months ended September 30, 2025, and related management discussion and analysis. ...

PITTSBURGH, Pa. and TORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeutics for genetic diseases, today announced that it will present preclinical data from its lead Phase 1 ready ‘901 program being developed to treat Gaucher disease and Glucocerebrosidase (GBA) Parkinson's disease at the World Orphan Drug Congress 2025. The meeting will take place from October 27 to 29, 2025, ...